Eloxx Pharmaceuticals Appoints Chief Medical Officer
September 08, 2021 08:00 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing...
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
August 16, 2021 16:05 ET
|
Eloxx Pharmaceuticals
Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Recessive Dystrophic...
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
July 06, 2021 16:15 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for...
Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents
May 27, 2021 08:30 ET
|
Eloxx Pharmaceuticals
Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment of...
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 18, 2021 14:15 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
May 14, 2021 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...
Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
May 13, 2021 16:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
May 06, 2021 17:15 ET
|
Eloxx Pharmaceuticals
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoing Phase 2 Clinical...
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
April 29, 2021 16:15 ET
|
Eloxx Pharmaceuticals
Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment Arms On Track for Second Half of 2021 WALTHAM, Mass., April...
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
April 01, 2021 07:45 ET
|
Eloxx Pharmaceuticals
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds...